サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1694644

非結核性抗酸菌症の世界市場：2025年

Nontuberculous Mycobacterial Infection Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
非結核性抗酸菌症の世界市場：2025年
出版日: 2025年03月04日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

非結核性抗酸菌症（NTM）の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.7％で195億7,000万米ドルに成長すると予測されています。予測期間の成長は、抗菌薬開発、非結核性抗酸菌症への意識の高まり、遺伝子研究の進歩、遠隔医療、遠隔モニタリングに起因すると考えられます。予測期間の主な動向には、個別化治療、規制の重点化、併用療法、デジタルヘルスツールなどがあります。

慢性閉塞性肺疾患（COPD）の有病率の上昇が、今後の非結核性抗酸菌感染症市場の成長を牽引するとみられます。COPDは、持続的かつ進行性の肺気流制限を特徴とする慢性呼吸器疾患であり、非結核性抗酸菌（NTM）感染と密接に関連しているため、強制呼気1秒量（FEV1）がより顕著に低下し、増悪率が上昇します。COPDによる免疫力の低下と肺組織の損傷により、NTM菌による肺感染症にかかりやすくなります。例えば、2023年3月現在、スコットランドの公衆衛生機関であるThe Scottish Public Health Observatory（ScotPHO）は、2021年から2022年にかけてCOPDの罹患率が上昇し、男性の罹患率は10万人あたり83.2人から97.6人に、女性の罹患率は72.6人から97.3人に上昇したと報告しています。その結果、慢性閉塞性肺疾患（COPD）の急増する有病率が非結核性抗酸菌感染症市場の成長を促進します。

感染症有病率の上昇は、今後数年間、非結核性抗酸菌（NTM）感染症市場の拡大を促進すると予想されます。感染症は、細菌、ウイルス、真菌、寄生虫などの有害な微生物によって引き起こされる病気で、個人間で感染し、さまざまな症状や健康合併症を引き起こします。NTM感染症を含む感染症の発生率が上昇するにつれて、NTM感染症市場は成長を遂げる可能性があります。これは、これらの感染症に対する認識が高まり、診断検査の頻度が増え、早期発見が可能になり、NTM治療薬の研究開発が強化され、感染症に対する医療の関心が高まるにつれてNTM病原体を標的とした治療薬に対する需要が高まるためです。例えば、米国を拠点とする政府間組織である国連国際児童緊急基金（UNICEF）は2024年11月、肺炎が年間70万人以上の子どもの死亡の原因となる主要な感染症であり、これは1日当たり約2,000人の死亡に相当すると報告しています。したがって、感染症の流行が増加していることが、NTM感染症市場の成長を促進しています。

当レポートは、世界の非結核性抗酸菌症市場について調査し、市場の概要とともに、薬剤クラス別、投与経路別、流通チャネル別、タイプ別、地域・国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 非結核性抗酸菌感染症市場の特徴

第3章 非結核性抗酸菌感染症の市場動向と戦略

第4章 非結核性抗酸菌感染症市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の非結核性抗酸菌感染症の拡大分析と戦略分析の枠組み

  • 世界の非結核性抗酸菌感染症のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の非結核性抗酸菌感染症市場の成長率分析
  • 世界の非結核性抗酸菌感染症の市場規模実績と成長、2019年～2024年
  • 世界の非結核性抗酸菌感染症の市場規模と成長予測、2024年～2029年、2034年予想
  • 世界の非結核性抗酸菌感染症の総獲得可能市場（TAM）

第6章 非結核性抗酸菌感染症の市場セグメンテーション

  • 世界の非結核性抗酸菌感染症市場、薬剤クラス別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年、2034年
  • マクロライド
  • リファンピシン
  • アミノグリコシド
  • その他
  • 世界の非結核性抗酸菌感染症市場、投与経路別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年、2034年
  • 経口
  • 非経口
  • その他
  • 世界の非結核性抗酸菌感染症市場、流通チャネル別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年、2034年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界の非結核性抗酸菌感染症市場、マクロライドのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年、2034年
  • アジスロマイシン
  • クラリスロマイシン
  • 世界の非結核性抗酸菌感染症市場、リファンピシンのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年、2034年
  • リファンピシン
  • リファブチン
  • 世界の非結核性抗酸菌感染症市場、アミノグリコシドのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年、2034年
  • アミカシン
  • ストレプトマイシン
  • 世界の非結核性抗酸菌感染症市場、その他の薬剤クラスのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
  • エタンブトール
  • クロファジミン
  • リネゾリド

第7章 非結核性抗酸菌感染症市場の地域別・国別分析

  • 世界の非結核性抗酸菌感染症市場、地域別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
  • 世界の非結核性抗酸菌感染症市場、国別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測

第8章 アジア太平洋の非結核性抗酸菌感染症市場

第9章 中国の非結核性抗酸菌感染症市場

第10章 インドの非結核性抗酸菌感染症市場

第11章 日本の非結核性抗酸菌感染症市場

第12章 オーストラリアの非結核性抗酸菌感染症市場

第13章 インドネシアの非結核性抗酸菌感染症市場

第14章 韓国の非結核性抗酸菌感染症市場

第15章 西欧の非結核性抗酸菌感染症市場

第16章 英国の非結核性抗酸菌感染症市場

第17章 ドイツの非結核性抗酸菌感染症市場

第18章 フランスの非結核性抗酸菌感染症市場

第19章 イタリアの非結核性抗酸菌感染症市場

第20章 スペインの非結核性抗酸菌感染症市場

第21章 東欧の非結核性抗酸菌感染症市場

第22章 ロシアの非結核性抗酸菌感染症市場

第23章 北米の非結核性抗酸菌感染症市場

第24章 米国の非結核性抗酸菌感染症市場

第25章 カナダの非結核性抗酸菌感染症市場

第26章 南米の非結核性抗酸菌感染症市場

第27章 ブラジルの非結核性抗酸菌感染症市場

第28章 中東の非結核性抗酸菌感染症市場

第29章 アフリカの非結核性抗酸菌感染症市場

第30章 非結核性抗酸菌感染症市場の競合情勢と企業プロファイル

  • 非結核性抗酸菌感染症市場の競合情勢
  • 非結核性抗酸菌感染症市場企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson
    • F. Hoffman La Roche AG
    • Merck &Co. Inc.
    • AbbVie Inc.

第31章 非結核性抗酸菌感染症市場その他の大手企業と革新的企業

  • Bayer AG
  • Novartis AG
  • Sanofi S.A.
  • Bristol Myers Squibb
  • AstraZeneca plc
  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company
  • Eli Lilly and Company
  • C.H. Boehringer Sohn AG & Co. KG
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Astellas Pharma Inc.
  • Vertex Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries Ltd.

第32章 世界の非結核性抗酸菌感染症市場の競合ベンチマーキングとダッシュボード

第33章 非結核性抗酸菌感染症市場における主要な合併と買収

第34章 非結核性抗酸菌感染症市場の最近の動向

第35章 非結核性抗酸菌感染症市場の潜在性が高い国、セグメント、戦略

  • 2029年の非結核性抗酸菌感染症市場- 最も新しい機会を提供する国
  • 2029年の非結核性抗酸菌感染症市場- 最も新しい機会を提供するセグメント
  • 2029年の非結核性抗酸菌感染症市場- 成長戦略
    • 市場動向に基づく戦略
    • 競合戦略

第36章 付録

目次
Product Code: r28621

A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than Mycobacterium tuberculosis, which is responsible for tuberculosis (TB). NTM infections are primarily significant due to their impact on human health and their interaction with the immune system.

The primary classes of drugs used to treat nontuberculous mycobacterial infections include macrolides, rifampin, aminoglycosides, and others. Macrolides are a class of antibiotics commonly employed in the treatment of various bacterial infections. These drugs can be administered through different routes, including oral, parenteral (injectable), and others, and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The nontuberculous mycobacterial infection market research report is one of a series of new reports from The Business Research Company that provides nontuberculous mycobacterial infection market statistics, including nontuberculous mycobacterial infection industry global market size, regional shares, competitors with a nontuberculous mycobacterial infection market share, detailed nontuberculous mycobacterial infection market segments, market trends and opportunities and any further data you may need to thrive in the nontuberculous mycobacterial infection industry. This nontuberculous mycobacterial infection market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $14.25 billion in 2024 to $15.11 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to improved diagnostics, aging population, cystic fibrosis awareness, immunosuppressive medications.

The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to $19.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to antimicrobial drug development, increasing ntm awareness, advances in genetic research, telehealth and remote monitoring. Major trends in the forecast period include personalized treatment, regulatory focus, combination therapies, digital health tools.

The increasing prevalence of chronic obstructive pulmonary disease (COPD) is set to drive the growth of the nontuberculous mycobacterial infection market in the future. COPD, a chronic respiratory ailment characterized by persistent and often progressive lung airflow limitation, is closely linked to nontuberculous mycobacterial (NTM) infections, resulting in a more pronounced decline in forced expiratory volume in one second (FEV1) and an elevated exacerbation rate. The weakened immune system and lung tissue damage caused by COPD make it more susceptible to NTM bacterial lung infections. For example, as of March 2023, The Scottish Public Health Observatory (ScotPHO), a public health body in Scotland, reported a rise in COPD rates from 2021 to 2022, with male rates increasing from 83.2 to 97.6 per 100,000 individuals, and female rates rising from 72.6 to 97.3. Consequently, the burgeoning prevalence of chronic obstructive pulmonary disease (COPD) propels the nontuberculous mycobacterial infection market's growth.

The growing prevalence of infectious diseases is expected to drive the expansion of the nontuberculous mycobacterial (NTM) infection market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms, such as bacteria, viruses, fungi, or parasites, that can be transmitted between individuals, leading to a range of symptoms and health complications. As the incidence of infectious diseases, including those that can lead to NTM infections, rises, the market for NTM infections may experience growth. This is due to increased awareness of these infections, leading to more frequent diagnostic testing, earlier detection, enhanced research and development for NTM treatments, and a higher demand for therapies targeting NTM pathogens as healthcare attention on infectious diseases intensifies. For example, in November 2024, the United Nations International Children's Emergency Fund (UNICEF), a US-based intergovernmental organization, reported that pneumonia was the leading infectious disease responsible for the deaths of over 700,000 children annually, equating to around 2,000 deaths per day. Therefore, the rising prevalence of infectious diseases is driving the growth of the NTM infection market.

Leading companies in the nontuberculous mycobacterial (NTM) infection market are adopting new treatment approval strategies, such as Fast Track designation for drug approvals, to maintain their market position. The Fast Track designation, granted by the FDA, is a process that accelerates the development and review of drugs intended for serious conditions with unmet medical needs. For example, in July 2022, the U.S.-based Food and Drug Administration (FDA) granted Fast Track Designation to NUZYRA for the treatment of NTM lung disease caused by Mycobacterium avium complex (MAC). NUZYRA (omadacycline) is an innovative broad-spectrum antibiotic developed to fight serious bacterial infections, including those caused by resistant strains. This designation helps speed up the development and review process for NUZYRA, addressing critical unmet medical needs.

In February 2023, Qurient Co. Ltd., a Korea-based biotech company, entered into a partnership with TB Alliance with the goal of developing telacebec, a drug for the treatment of tuberculosis and other nontuberculous mycobacterial (NTM) infections. The partnership grants TB Alliance the exclusive global license for Telacebec. This signifies that TB Alliance will have the authority to continue its work on the medicine and market it on an international scale. TB Alliance, a South Africa-based non-profit organization, is dedicated to developing and delivering cost-effective TB medications.

Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nontuberculous mycobacterial infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The nontuberculous mycobacterial infection market consists of revenues earned by entities by providing services such as treatment planning, antibiotic therapy, monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The nontuberculous mycobacterial infection market also includes sales of azithromycin, rifampin, ethambutol, streptomycin, medical equipment, pulmonary rehabilitation and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nontuberculous Mycobacterial Infection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nontuberculous mycobacterial infection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nontuberculous mycobacterial infection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nontuberculous mycobacterial infection market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug Class: Macrolides; Rifampin; Aminoglycoside; Other Drug Classes
  • 2) By Route Of Administration: Oral; Parenteral; Other Routes
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Subsegments:
  • 1) By Macrolides: Azithromycin; Clarithromycin
  • 2) By Rifampin: Rifampin; Rifabutin
  • 3) By Aminoglycoside: Amikacin; Streptomycin
  • 4) By Other Drug Classes: Ethambutol; Clofazimine; Linezolid
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffman La Roche AG; Merck & Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nontuberculous Mycobacterial Infection Market Characteristics

3. Nontuberculous Mycobacterial Infection Market Trends And Strategies

4. Nontuberculous Mycobacterial Infection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Nontuberculous Mycobacterial Infection Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Nontuberculous Mycobacterial Infection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Nontuberculous Mycobacterial Infection Market Growth Rate Analysis
  • 5.4. Global Nontuberculous Mycobacterial Infection Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Nontuberculous Mycobacterial Infection Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Nontuberculous Mycobacterial Infection Total Addressable Market (TAM)

6. Nontuberculous Mycobacterial Infection Market Segmentation

  • 6.1. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Macrolides
  • Rifampin
  • Aminoglycoside
  • Other Drug Classes
  • 6.2. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Parenteral
  • Other Routes
  • 6.3. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.4. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Macrolides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Azithromycin
  • Clarithromycin
  • 6.5. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Rifampin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Rifampin
  • Rifabutin
  • 6.6. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Aminoglycoside, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Amikacin
  • Streptomycin
  • 6.7. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ethambutol
  • Clofazimine
  • Linezolid

7. Nontuberculous Mycobacterial Infection Market Regional And Country Analysis

  • 7.1. Global Nontuberculous Mycobacterial Infection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Nontuberculous Mycobacterial Infection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nontuberculous Mycobacterial Infection Market

  • 8.1. Asia-Pacific Nontuberculous Mycobacterial Infection Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nontuberculous Mycobacterial Infection Market

  • 9.1. China Nontuberculous Mycobacterial Infection Market Overview
  • 9.2. China Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nontuberculous Mycobacterial Infection Market

  • 10.1. India Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nontuberculous Mycobacterial Infection Market

  • 11.1. Japan Nontuberculous Mycobacterial Infection Market Overview
  • 11.2. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nontuberculous Mycobacterial Infection Market

  • 12.1. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nontuberculous Mycobacterial Infection Market

  • 13.1. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nontuberculous Mycobacterial Infection Market

  • 14.1. South Korea Nontuberculous Mycobacterial Infection Market Overview
  • 14.2. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nontuberculous Mycobacterial Infection Market

  • 15.1. Western Europe Nontuberculous Mycobacterial Infection Market Overview
  • 15.2. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nontuberculous Mycobacterial Infection Market

  • 16.1. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nontuberculous Mycobacterial Infection Market

  • 17.1. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nontuberculous Mycobacterial Infection Market

  • 18.1. France Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nontuberculous Mycobacterial Infection Market

  • 19.1. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nontuberculous Mycobacterial Infection Market

  • 20.1. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nontuberculous Mycobacterial Infection Market

  • 21.1. Eastern Europe Nontuberculous Mycobacterial Infection Market Overview
  • 21.2. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nontuberculous Mycobacterial Infection Market

  • 22.1. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nontuberculous Mycobacterial Infection Market

  • 23.1. North America Nontuberculous Mycobacterial Infection Market Overview
  • 23.2. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nontuberculous Mycobacterial Infection Market

  • 24.1. USA Nontuberculous Mycobacterial Infection Market Overview
  • 24.2. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nontuberculous Mycobacterial Infection Market

  • 25.1. Canada Nontuberculous Mycobacterial Infection Market Overview
  • 25.2. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nontuberculous Mycobacterial Infection Market

  • 26.1. South America Nontuberculous Mycobacterial Infection Market Overview
  • 26.2. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nontuberculous Mycobacterial Infection Market

  • 27.1. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nontuberculous Mycobacterial Infection Market

  • 28.1. Middle East Nontuberculous Mycobacterial Infection Market Overview
  • 28.2. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nontuberculous Mycobacterial Infection Market

  • 29.1. Africa Nontuberculous Mycobacterial Infection Market Overview
  • 29.2. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nontuberculous Mycobacterial Infection Market Competitive Landscape And Company Profiles

  • 30.1. Nontuberculous Mycobacterial Infection Market Competitive Landscape
  • 30.2. Nontuberculous Mycobacterial Infection Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. F. Hoffman La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nontuberculous Mycobacterial Infection Market Other Major And Innovative Companies

  • 31.1. Bayer AG
  • 31.2. Novartis AG
  • 31.3. Sanofi S.A.
  • 31.4. Bristol Myers Squibb
  • 31.5. AstraZeneca plc
  • 31.6. Abbott Laboratories
  • 31.7. GlaxoSmithKline plc
  • 31.8. Takeda Pharmaceutical Company
  • 31.9. Eli Lilly and Company
  • 31.10. C.H. Boehringer Sohn AG & Co. KG
  • 31.11. Teva Pharmaceutical Industries Ltd.
  • 31.12. Mylan N.V.
  • 31.13. Astellas Pharma Inc.
  • 31.14. Vertex Pharmaceuticals Inc.
  • 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Nontuberculous Mycobacterial Infection Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nontuberculous Mycobacterial Infection Market

34. Recent Developments In The Nontuberculous Mycobacterial Infection Market

35. Nontuberculous Mycobacterial Infection Market High Potential Countries, Segments and Strategies

  • 35.1 Nontuberculous Mycobacterial Infection Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Nontuberculous Mycobacterial Infection Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Nontuberculous Mycobacterial Infection Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer